• 1
    A Gallup Organizational National Survey. Heartburn Across America. Princeton, NJ: The Gallup Organization, Inc, 1988.
  • 2
    Eisen G. The epidemiology of gastroesophageal reflux disease: what we know and what we need to know. Amer J Gastro 2001; 96(Suppl. 8): S168.
  • 3
    Johanson JF. Epidemiology of esophageal and supraesophageal reflux injuries. Amer J Med 2000; 108(Suppl. 4A): 99S103S.
  • 4
    Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 144856.
  • 5
    Frank L, Kleinman L, Ganoczy D, et al. Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilization and quality of life. Digest Dis Sci 2000; 45: 80918.
  • 6
    Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Amer J Epidemiol 1992; 136: 16577.
  • 7
    Greenberger NJ. Update in gastroenterology. Ann Intern Med 1998; 129: 30916.
  • 8
    Bloom BS, Jayadevappa R, Wahl P, Cacciamanni J. Time trends in cost of caring for people with gastroesophageal reflux disease. Amer J Gastro 2001; 96(Suppl. 8): S649.
  • 9
    Fendrick AM. Management of patients with symptomatic gastroesophageal reflux disease: a primary care perspective. Amer J Gastro 2001; 96(Suppl. 8): S2933.
  • 10
    Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 110610.
  • 11
    Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 96573.
  • 12
    Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118: S9S31.
  • 13
    Hatlebakk JG, Katz PO, Castell DO. Gastroesophageal reflux disease: medical therapy: management of the refractory patient. Gastro Clinics 1999; 28: 84760.
  • 14
    Katz PO. Lessons learned from intragastric pH monitoring. J Clin Gastroenterol 2001; 33: 10713.
  • 15
    Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects of gastric and esophageal pH and serum gastrin in healthy controls. Amer J Gastroenterol 1996; 91: 15328.
  • 16
    Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharm Ther 2000; 14: 126772.